Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-12-29

Clinical Trial Update: Glycine vs Placebo for the Schizophrenia Prodrome [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial comparing glycine to placebo in individuals at risk for schizophrenia shows completed status with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Glycine (glycine)

Snippet

Sponsor: Yale University | Conditions: Schizophrenia Prodrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-12-29